Patents by Inventor Barry Polisky

Barry Polisky has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240118283
    Abstract: The present invention relates to, inter alia, engineered microorganisms expressing (i) a surface protein, which specifically interacts cell membrane receptors that are specifically exposed to the luminal side of epithelial cells of diseased gastrointestinal tissue, and (ii) a secretable biomarker. The engineered bacteria of the present technology are useful for detecting diseased gastrointestinal tissue.
    Type: Application
    Filed: December 8, 2023
    Publication date: April 11, 2024
    Inventors: Jeffrey Wagner, Fred H. Mermelstein, Carl D. Novina, Robert Distel, Steven Neier, Barry Polisky
  • Publication number: 20090299045
    Abstract: This invention relates to compounds, compositions, and methods useful for modulating interleukin and/or interleukin receptor gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of interleukin and/or interleukin receptor gene expression and/or activity by RNA interference (RNAi) using small nucleic acid molecules.
    Type: Application
    Filed: May 31, 2007
    Publication date: December 3, 2009
    Applicant: SIRNA THERAPEUTICS, INC.
    Inventors: Ivan Richards, Barry Polisky, James McSwiggen
  • Publication number: 20090023676
    Abstract: The present invention concerns methods and reagents useful in modulating MAP kinase gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules capable of mediating RNA interference (RNAi) against c-JUN, JNK, p38, and ERK gene expression, useful in the treatment of cancer, inflammation, obesity and insulin resistance (e.g. Type I and Type II diabetes).
    Type: Application
    Filed: August 29, 2008
    Publication date: January 22, 2009
    Applicant: Sirna Therapeutics, Inc.
    Inventors: James McSwiggen, Leonid Beigelman, Nassim Usman, Peter Haeberli, Bharat M. Chowrira, Barry Polisky
  • Publication number: 20070173467
    Abstract: This invention relates to compounds, compositions, and methods useful for modulating cholesteryl ester transfer protein (CETP) gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of CETP gene expression and/or activity by RNA interference (RNAi) using small nucleic acid molecules. In particular, the instant invention features small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules and methods used to modulate the expression of CETP genes.
    Type: Application
    Filed: August 19, 2004
    Publication date: July 26, 2007
    Applicant: Sirna Therapeutics, Inc.
    Inventors: James McSwiggen, Barry Polisky
  • Publication number: 20060142226
    Abstract: This invention relates to compounds, compositions, and methods useful for modulating cholesteryl ester transfer protein (CETP) gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of CETP gene expression and/or activity by RNA interference (RNAi) using small nucleic acid molecules. In particular, the instant invention features small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules and methods used to modulate the expression of CETP genes.
    Type: Application
    Filed: August 19, 2004
    Publication date: June 29, 2006
    Applicant: Sirna Therapeutics, Inc.
    Inventors: Barry Polisky, James McSwiggen
  • Publication number: 20060127891
    Abstract: The present invention concerns methods and reagents useful in modulating MAP kinase gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules capable of mediating RNA interference (RNAi) against c-JUN, JNK, p38, and ERK gene expression, useful in the treatment of cancer, inflammation, obesity and insulin resistance (e.g. Type I and Type II diabetes).
    Type: Application
    Filed: April 25, 2003
    Publication date: June 15, 2006
    Inventors: James McSwiggen, Leonid Beigelman, Nassim Usman, Peter Haeberli, Bharat Chowrira, Barry Polisky
  • Publication number: 20050261219
    Abstract: This invention relates to compounds, compositions, and methods useful for modulating interleukin and/or interleukin receptor gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of interleukin and/or interleukin receptor gene expression and/or activity by RNA interference (RNAi) using small nucleic acid molecules.
    Type: Application
    Filed: December 1, 2004
    Publication date: November 24, 2005
    Applicant: Sirna Therapeutics, Inc.
    Inventors: Ivan Richards, Barry Polisky, James McSwiggen
  • Publication number: 20050176666
    Abstract: This invention relates to compounds, compositions, and methods useful for modulating G protein-coupled receptor for asthma susceptibility (GPRA) and asthma-associated alternatively spliced gene 1 (AAA1) gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of GPRA and/or AAA1 gene expression and/or activity by RNA interference (RNAi) using small nucleic acid molecules. In particular, the instant invention features small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules and methods used to modulate the expression of GPRA and/or AAA1 genes.
    Type: Application
    Filed: August 20, 2004
    Publication date: August 11, 2005
    Applicant: Sirna Therapeutics, Inc.
    Inventors: Ivan Richards, Barry Polisky, James McSwiggen
  • Publication number: 20050171040
    Abstract: This invention relates to compounds, compositions, and methods useful for modulating cholesteryl ester transfer protein (CETP) gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of CETP gene expression and/or activity by RNA interference (RNAi) using small nucleic acid molecules. In particular, the instant invention features small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules and methods used to modulate the expression of CETP genes.
    Type: Application
    Filed: June 9, 2004
    Publication date: August 4, 2005
    Applicant: Sirna Therapeutics, Inc.
    Inventors: Barry Polisky, James McSwiggen
  • Publication number: 20050142578
    Abstract: The present invention concerns methods and reagents useful in target discovery. Specifically, the invention relates to small nucleic acid molecules capable of mediating RNA interference (RNAi), such as short interfering nucleic acid (siNA) short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules and methods of target discovery using siRNA.
    Type: Application
    Filed: August 19, 2004
    Publication date: June 30, 2005
    Applicant: Sirn Therapeutics, Inc.
    Inventors: Nassim Usman, Barry Polisky, James Thompson, Leonid Beigelman
  • Publication number: 20050143333
    Abstract: This invention relates to compounds, compositions, and methods useful for modulating interleukin and/or interleukin receptor gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of interleukin and/or interleukin receptor gene expression and/or activity by RNA interference (RNAi) using small nucleic acid molecules.
    Type: Application
    Filed: June 9, 2004
    Publication date: June 30, 2005
    Applicant: Sirna Therapeutics, Inc.
    Inventors: Ivan Richards, Barry Polisky, James McSwiggen
  • Publication number: 20050079610
    Abstract: This invention relates to compounds, compositions, and methods useful for modulating c-Fos gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of c-Fos gene expression and/or activity by RNA interference (RNAi) using small nucleic acid molecules. In particular, the instant invention features small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules and methods used to modulate the expression of c-Fos genes.
    Type: Application
    Filed: August 20, 2004
    Publication date: April 14, 2005
    Applicant: Sirna Therapeutics, Inc.
    Inventors: Barry Polisky, James McSwiggen, Leonid Beigelman
  • Patent number: 5580737
    Abstract: Methods are described for the identification and preparation of nucleic acid ligand ligands to theophylline and caffeine. Included in the invention is a method for identifying nucleic acid ligands with high affinity and selectivity for a target molecule, termed counter-SELEX.
    Type: Grant
    Filed: May 18, 1995
    Date of Patent: December 3, 1996
    Assignee: NeXstar Pharmaceuticals, Inc.
    Inventors: Barry Polisky, Robert D. Jenison, Larry Gold